var data={"title":"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/contributors\" class=\"contributor contributor_credentials\">Andr&eacute; Lacroix, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/contributors\" class=\"contributor contributor_credentials\">Lynnette K Nieman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/contributors\" class=\"contributor contributor_credentials\">Kathryn A Martin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 21, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among the causes of Cushing's syndrome are three rare types of nodular adrenocortical diseases that are usually bilateral:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Corticotropin (ACTH)-dependent bilateral macronodular adrenal hyperplasia, secondary to long-term adrenal stimulation in patients with Cushing's disease or ectopic ACTH syndrome. However, the adrenals rarely reach the massive size that can be seen with primary bilateral macronodular adrenal hyperplasia, and plasma ACTH may still be detectable.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ACTH-independent micronodular adrenal hyperplasia and its most frequent variant, primary pigmented nodular adrenocortical disease (PPNAD), which may be sporadic or familial (as part of the Carney complex).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary bilateral macronodular adrenal hyperplasia (BMAH), a disorder previously referred to as ACTH-independent bilateral macronodular adrenal hyperplasia (AIMAH).</p><p/><p>BMAH will be reviewed here. Other causes of Cushing's syndrome and PPNAD are discussed separately. (See <a href=\"topic.htm?path=causes-and-pathophysiology-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Causes and pathophysiology of Cushing's syndrome&quot;</a> and <a href=\"topic.htm?path=cushings-syndrome-due-to-primary-pigmented-nodular-adrenocortical-disease\" class=\"medical medical_review\">&quot;Cushing's syndrome due to primary pigmented nodular adrenocortical disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1559178543\"><span class=\"h1\">OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary bilateral macronodular adrenal hyperplasia (BMAH or PBMAH) has been described by various terms, including corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH), primary macronodular adrenal hyperplasia (PMAH), massive macronodular adrenocortical disease (MMAD), autonomous macronodular adrenal hyperplasia (AMAH), ACTH-independent massive bilateral adrenal disease (AIMBAD), and &quot;giant&quot; or &quot;huge&quot; macronodular adrenal disease. However, we prefer and use bilateral macronodular adrenal hyperplasia (BMAH) here.</p><p>Primary bilateral macronodular adrenal hyperplasia (BMAH) is an <strong>uncommon</strong> cause (&lt;2 percent) of endogenous Cushing's syndrome, characterized by enlarged adrenal glands containing multiple nonpigmented nodules that are greater than 10 mm in diameter but can be as large as 30 to 40 mm in diameter [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/1\" class=\"abstract_t\">1</a>]. It can be diagnosed in patients with Cushing's syndrome but more often in those with incidentally found bilateral macronodular adrenals and subclinical secretion of cortisol who are between the ages of 40 and 60 years; as 10 to 15 percent of adrenal incidentalomas are bilateral, BMAH is one of the causes of bilateral adrenal incidentalomas, but its precise prevalence has not been determined in population studies.</p><p>Aside from BMAH, the differential diagnosis of bilateral adrenal incidentalomas includes disorders that are <strong>not</strong> associated with cortisol excess: bilateral adrenal adenomas, pheochromocytomas, metastasis, congenital adrenal hyperplasia (CAH), hemorrhage, lymphoma, and infiltrative and infectious diseases (see <a href=\"topic.htm?path=the-adrenal-incidentaloma\" class=\"medical medical_review\">&quot;The adrenal incidentaloma&quot;</a>). In BMAH, plasma ACTH levels become progressively suppressed when cortisol secretion is sufficiently elevated (increased urinary free cortisol [UFC] levels).</p><p>Treatment of BMAH is usually surgical; bilateral adrenalectomy is indicated in most patients with BMAH and severe Cushing's syndrome (UFC &gt;3 times upper limit of normal), but unilateral adrenalectomy can normalize UFC in some patients with mild Cushing's syndrome. In patients in whom aberrant hormone receptors have been identified, specific pharmacologic therapies have been utilized in some cases as alternatives to adrenalectomy. (See <a href=\"#H21362891\" class=\"local\">'Pharmacologic therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H668811581\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Aberrant hormone receptors, local production of corticotropin (ACTH) in adrenal tissues, and genetic mutations have been identified in the pathogenesis of primary BMAH.</p><p class=\"headingAnchor\" id=\"H668811619\"><span class=\"h2\">Aberrant hormone receptors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most prevalent abnormality in patients with BMAH results from the aberrant adrenal expression of ectopic receptors or increased activity of eutopic peptide hormone receptors (<a href=\"image.htm?imageKey=ENDO%2F65003\" class=\"graphic graphic_table graphicRef65003 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Cortisol secretion becomes driven by a hormone that escapes cortisol-mediated feedback. In a series of patients with BMAH (and mild or overt Cushing's syndrome) who were screened for aberrant receptors, more than 85 percent had at least one and usually several aberrant responses (most commonly to <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> and serotonin 5-hydroxytryptamine 4 [5-HT4] agonists) [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/4-8\" class=\"abstract_t\">4-8</a>]. Examples of aberrant receptors include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">Vasopressin</a><strong> </strong>&ndash;<strong> </strong>Vasopressin-responsive Cushing's syndrome is the most frequent aberrant stimulator of cortisol secretion in patients with BMAH. In these patients, cortisol secretion increases with upright posture or other physiological stimuli of endogenous vasopressin, such as hypertonic saline infusion [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/2,3,6,9-16\" class=\"abstract_t\">2,3,6,9-16</a>]. In most, cortisol secretion was regulated by the V1-vasopressin receptor (no stimulation by <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>, a preferential V2 receptor agonist), expressed at either normal or high levels.</p><p/><p class=\"bulletIndent1\">The V1-vasopressin receptor is normally expressed in the adrenal cortex but is not a major regulator of steroidogenesis. In patients with BMAH, the exaggerated steroidogenic responses to <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> are secondary to the increased activity <span class=\"nowrap\">and/or</span> expression of a &quot;eutopic&quot; receptor-effector system.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Beta-adrenergic </strong>&ndash;<strong> </strong>BMAH and Cushing's syndrome have been reported in patients with aberrant adrenal expression of beta-adrenergic receptors. Plasma cortisol and aldosterone levels increase in response to elevations in endogenous catecholamines that occur with upright posture, insulin-induced hypoglycemia, and exercise [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/17\" class=\"abstract_t\">17</a>]. <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">Isoproterenol</a> infusion stimulates cortisol and aldosterone secretion, and <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a> blocks this effect and reduces basal cortisol secretion with long-term control of hypercortisolism [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/18\" class=\"abstract_t\">18</a>]. These effects were not seen in normal subjects. Similar findings have been reported in other patients with BMAH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/6,14,19\" class=\"abstract_t\">6,14,19</a>]. High-affinity binding sites compatible with beta-1- or beta-2-adrenergic receptors were efficiently coupled to steroidogenesis in the adrenal tissues in these patients, but not in controls, indicating the ectopic nature of this receptor [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/14,17,19\" class=\"abstract_t\">14,17,19</a>].</p><p/><p class=\"bulletIndent1\">The combined presence of adrenal beta-adrenergic receptor and V1-vasopressin receptor has been observed in other patients with BMAH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/6,14,17,19\" class=\"abstract_t\">6,14,17,19</a>]. The combined overexpression of beta-2-adrenoreceptor, serotonin 5-HT4 receptor, and V1-vasopressin receptor also was demonstrated [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/18,20\" class=\"abstract_t\">18,20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">LH/hCG</span> </strong>&ndash; Hypercortisolism due to aberrant luteinizing hormone <span class=\"nowrap\">(LH)/human</span> chorionic gonadotropin (hCG) receptors was first identified in a woman with history of transient Cushing's syndrome during sequential pregnancies; however, persistent Cushing's syndrome and BMAH developed only after the postmenopausal sustained increase of LH secretion [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/21\" class=\"abstract_t\">21</a>]. Administration of the long-acting gonadotropin-releasing hormone (GnRH) agonist, <a href=\"topic.htm?path=leuprolide-drug-information\" class=\"drug drug_general\">leuprolide</a> acetate, resulted in suppression of endogenous LH and normalization of cortisol production [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/21\" class=\"abstract_t\">21</a>]. In a 22-year-old woman who presented with transient, bilateral adrenal hyperplasia and severe Cushing's syndrome during two pregnancies, in vivo and in vitro studies in resected adrenals demonstrated that hCG could stimulate the transformation of progenitor subcapsular adrenal <span class=\"nowrap\">LH/hCG</span> receptor-expressing cells into hyperplastic adrenocortical cells, increasing their steroidogenesis under hCG stimulation [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/22\" class=\"abstract_t\">22</a>]. In a 59-year-old woman with androgen-secreting BMAH resulting in virilization, aberrant <span class=\"nowrap\">LH/hCG</span> receptors were identified in one resected adrenal. Suppression of endogenous LH with leuprolide acetate normalized androgen secretion from the contralateral adrenal, thereby avoiding bilateral adrenalectomy [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Serotonin</strong> &ndash;<strong> </strong>Other cases of aberrant receptors for <span class=\"nowrap\">LH/hCG</span> or serotonin, either alone or in combination, have been reported [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/9,10,24\" class=\"abstract_t\">9,10,24</a>]. In one of the patients described above [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/21\" class=\"abstract_t\">21</a>], serotonin 5-HT4 receptor agonists, cisapride and <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">metoclopramide</a>, also stimulated plasma cortisol.</p><p/><p class=\"bulletIndent1\">Following the initial description of combined aberrant LH and serotonin 5-HT4 receptors in BMAH, several other patients were found to have increased secretion of cortisol following stimulation with cisapride, <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">metoclopramide</a>, or <a href=\"topic.htm?path=tegaserod-united-states-available-via-fda-emergency-access-protocol-only-drug-information\" class=\"drug drug_general\">tegaserod</a> [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/9,10,16,24-27\" class=\"abstract_t\">9,10,16,24-27</a>]. In most cases, a large overexpression of 5-HT4 receptor was found in the adrenals [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/28-30\" class=\"abstract_t\">28-30</a>]. The ectopic expression and function of serotonin 5-hydroxytryptamine 7 (5-HT7) receptor was identified in a patient with serotonin-responsive BMAH and Cushing's syndrome [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>GIP </strong>&ndash;<strong> </strong>The ectopic expression of glucose-dependent insulinotropic peptide (also known as gastric inhibitory polypeptide [GIP]) receptor in zona fasciculata cells causes <strong>&quot;food-dependent&quot; cortisol production</strong>. Plasma cortisol levels may be relatively low during fasting and increase transiently following meals [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/31-33\" class=\"abstract_t\">31-33</a>]. GIP-dependent Cushing's syndrome has been reported in approximately 20 patients with BMAH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/31-37\" class=\"abstract_t\">31-37</a>]. GIP receptors are not expressed in the normal adult or fetal zona fasciculata [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/33-36,38\" class=\"abstract_t\">33-36,38</a>].</p><p/><p class=\"bulletIndent1\">The adrenal nodules in some patients with GIP-dependent BMAH can progress asynchronously, first in one adrenal, later in the other [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/36\" class=\"abstract_t\">36</a>]; in one report, the adrenal adjacent to the macronodules was not atrophic but showed diffuse adrenal hyperplasia with ectopic GIP receptor expression [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/36\" class=\"abstract_t\">36</a>], suggesting that larger nodules were the result of secondary clonal proliferation events [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p class=\"bulletIndent1\">Other reported cases include patients with combined aberrant expression of GIP receptor and <span class=\"nowrap\">LH/hCG</span> receptor [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/10,40\" class=\"abstract_t\">10,40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Angiotensin</strong> &ndash;<strong> </strong>In a patient with BMAH and a large increase in plasma aldosterone and cortisol levels during upright posture, short-term oral administration of the angiotensin II receptor antagonist <a href=\"topic.htm?path=candesartan-drug-information\" class=\"drug drug_general\">candesartan</a> completely inhibited the elevation in cortisol and aldosterone [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/41\" class=\"abstract_t\">41</a>]. In vitro stimulation of cortisol secretion by angiotensin II was also found in patients with BMAH and Cushing's syndrome who had increases in cortisol levels with upright posture [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other receptors </strong>&ndash; In a study that looked to identify novel abnormally expressed G-protein-coupled receptors (GPCRs) in patients with BMAH, several new aberrant receptor genes were identified, one of which (the alpha-2A-adrenergic receptor [<em>ADRA2A</em>], highly expressed in 13 of 18 BMAHs) may be a potential target for pharmacologic treatment of Cushing's syndrome due to BMAH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/42\" class=\"abstract_t\">42</a>]. <a href=\"topic.htm?path=clonidine-drug-information\" class=\"drug drug_general\">Clonidine</a> (an <em>ADRA2A</em> agonist) administration resulted in an increase in cortisol production; the increase could be blocked by an <em>ADRA2A</em> antagonist, yohimbine. In other patients, the administration of <a href=\"topic.htm?path=glucagon-drug-information\" class=\"drug drug_general\">glucagon</a> increased plasma cortisol, while <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> inhibited plasma cortisol in patients with BMAH and mild Cushing's syndrome [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/4\" class=\"abstract_t\">4</a>] (see <a href=\"#H1559179074\" class=\"local\">'Screening for aberrant receptors'</a> below).</p><p/><p class=\"bulletIndent1\">It should be noted that some have maintained that the aberrant receptors may be a consequence rather than the cause of adrenal hyperplasia [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"headingAnchor\" id=\"H668811725\"><span class=\"h2\">Paracrine secretion of ACTH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The hypercortisolism associated with primary BMAH was previously considered to be corticotropin (ACTH) independent. However, it appears that cortisol secretion in BMAH is at least partially regulated by intraadrenal ACTH, which is produced by steroidogenic cells in the hyperplastic adrenals [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/44,45\" class=\"abstract_t\">44,45</a>].</p><p>In a report of 30 patients with BMAH, proopiomelanocortin (POMC) mRNA was detected in all 26 BMAH adrenal gland samples analyzed; <span class=\"nowrap\">moderate/intense</span> immunostaining for ACTH was detectable in clusters of steroidogenic cells in most samples [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/45\" class=\"abstract_t\">45</a>]. Conversely, no ACTH staining was present in normal adrenal cortex or cortisol-secreting adenomas [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/45\" class=\"abstract_t\">45</a>]. ACTH secretion was also confirmed by the demonstration of an ACTH gradient in adrenal vein sampling in two BMAH patients, but ACTH plasma levels remained low.</p><p>In vitro, adrenal ACTH secretion was not regulated by corticotropin-releasing hormone (CRH), <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, or <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a>. In contrast, tissues that expressed aberrant GPCRs released ACTH and cortisol during perifusion with GIP, serotonin, or hCG. ACTH receptor antagonists inhibited cortisol secretion by 40 percent in these tissues. Thus, in vitro studies show that cortisol production is apparently controlled both by aberrant GPCR and ACTH produced within the adrenocortical tissue, amplifying the effect of the aberrant receptors' ligands. The confirmation that paracrine adrenal production of ACTH and other peptides is central in cortisol regulation of BMAH will necessitate in vivo demonstration that inhibition of adrenal ACTH and other receptors reverses hypercortisolism in affected patients [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"headingAnchor\" id=\"H668811731\"><span class=\"h2\">Genetic causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several molecular causes have been identified in the pathogenesis of primary BMAH, indicating that it is a heterogeneous disease [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/5\" class=\"abstract_t\">5</a>]. Most cases of BMAH were thought to be sporadic [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/46-49\" class=\"abstract_t\">46-49</a>]. However, there are now several reports of familial cases of BMAH whose presentation suggests autosomal dominant transmission [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/14-16,50-55\" class=\"abstract_t\">14-16,50-55</a>].</p><p>In familial cases of BMAH, a number of aberrant hormone receptors, but no genetic abnormality, had been identified in individual families investigated initially, including V1-V2- and V3-vasopressin [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/15\" class=\"abstract_t\">15</a>], beta-adrenergic [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/53\" class=\"abstract_t\">53</a>], combined V1-vasopressin and beta-adrenergic [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/14,18\" class=\"abstract_t\">14,18</a>], and combined 5-HT4 and V1-V2-vasopressin [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/16\" class=\"abstract_t\">16</a>] (see <a href=\"#H668811619\" class=\"local\">'Aberrant hormone receptors'</a> above). Several genetic abnormalities have now been identified in BMAH kindreds.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>ARMC5</em> (armadillo repeat containing 5 gene) &ndash; Germline mutations of <em>ARMC5</em> are found in approximately 25 percent of apparently sporadic BMAH patients [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/56-59\" class=\"abstract_t\">56-59</a>]. <em>ARMC5</em> behaves as a tumor suppressor gene, and in one report, a different somatic <em>ARMC5</em> mutation or deletion was found in each adrenal nodule examined and appeared to accelerate the proliferation of affected cells [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/56,60\" class=\"abstract_t\">56,60</a>]. In two studies, a high percentage of first-degree relatives of the probands carried a germline <em>ARMC5</em> mutation and unsuspected BMAH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/56,58\" class=\"abstract_t\">56,58</a>].</p><p/><p class=\"bulletIndent1\">In one large family, which included 22 mutation carriers, two had Cushing's syndrome, 17 had only mild cortisol excess, while three patients aged 25, 29, or 76 years were silent carriers; in 6 of 22, only one adrenal was enlarged, suggesting variable penetrance of the <em>ARMC5</em> mutation [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/58\" class=\"abstract_t\">58</a>]. A high prevalence of biallelic <em>ARMC </em>mutations were identified in other families with BMAH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/18,61,62\" class=\"abstract_t\">18,61,62</a>]. The relationship between <em>ARMC5</em> mutations and aberrant receptors or ACTH expression has not been studied in detail yet; no <em>ARMC5</em> mutation carriers had GIP-dependent Cushing's syndrome, but some had aberrant regulation by <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a>, beta-adrenergic, and serotonin agonists [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/18,59,62\" class=\"abstract_t\">18,59,62</a>]. Somatic mutation of <em>ARMC5 </em>was also found in meningiomas, which can occur in familial BMAH, suggesting that other tumors could result from mutations of the <em>ARMC5</em> tumor suppressor gene (which is expressed in several human tissues) [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/15,37,58,62\" class=\"abstract_t\">15,37,58,62</a>].</p><p/><p class=\"bulletIndent1\">However, in patients with bilateral adrenal incidentalomas, germline ARMC5 mutations are rarely found [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/63\" class=\"abstract_t\">63</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cushing's syndrome associated with McCune-Albright syndrome (MAS) is a rare variant of BMAH that presents in infancy or childhood. MAS is a sporadic disease characterized by polyostotic fibrous dysplasia with caf&eacute; au lait spots, sexual precocity, and other endocrine and nonendocrine disorders [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/28,64\" class=\"abstract_t\">28,64</a>]. An activating somatic of the alpha-subunit stimulatory guanine nucleotide-binding protein, Gs, occurs in some adrenal cells in a mosaic pattern, which leads to the formation of adrenal nodules [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/65,66\" class=\"abstract_t\">65,66</a>]. Activating mutations of Gs alpha have been occasionally found in the BMAH nodules of pediatric or adult patients without any other features of MAS [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/66,67\" class=\"abstract_t\">66,67</a>]. (See <a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty#H3989453\" class=\"medical medical_review\">&quot;Definition, etiology, and evaluation of precocious puberty&quot;, section on 'McCune-Albright syndrome'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bilateral adrenal nodules also have been described as part of multiple endocrine neoplasia syndrome type 1 (MEN1). A retrospective analysis of 715 MEN1 patients found the presence of adrenal lesions in 20 percent, and of those with lesions &gt;1 cm, 12.9 percent had bilateral lesions without further evaluation of how many were BMAH; most unilateral or bilateral tumors were nonfunctional, but primary aldosteronism was more frequent than in a control group of adrenal incidentalomas without MEN1 [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/68\" class=\"abstract_t\">68</a>]. (See <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>BMAH or adrenal nodules have been reported in patients with familial adenomatous polyposis and a mutation in the adenomatous polyposis coli (<em>APC</em>) gene [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/5,69\" class=\"abstract_t\">5,69</a>] and with hereditary leiomyomatosis and renal cell cancer disorders due to mutations in the fumarate hydratase (<em>FH</em>) gene [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/70\" class=\"abstract_t\">70</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of familial adenomatous polyposis&quot;</a> and <a href=\"topic.htm?path=hereditary-kidney-cancer-syndromes#H3\" class=\"medical medical_review\">&quot;Hereditary kidney cancer syndromes&quot;, section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Missense germline mutations in phosphodiesterase 11A isoform 4 gene (<em>PDE11A</em>) have been identified initially in kindreds with nonpigmented micronodular hyperplasia but have now been found at higher frequency in patients with various adrenocortical tumors, including BMAH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/71\" class=\"abstract_t\">71</a>]. As noted above, BMAH is thus probably genetically heterogeneous, with occasional cases that occur in association with other syndromes [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/5,29,69,70,72,73\" class=\"abstract_t\">5,29,69,70,72,73</a>], and this has been reviewed in further detail [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/74-76\" class=\"abstract_t\">74-76</a>]. (See <a href=\"topic.htm?path=cushings-syndrome-due-to-primary-pigmented-nodular-adrenocortical-disease\" class=\"medical medical_review\">&quot;Cushing's syndrome due to primary pigmented nodular adrenocortical disease&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with BMAH and Cushing's syndrome typically present in the fifth and sixth decades [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/46-49\" class=\"abstract_t\">46-49</a>], a later age of onset compared with unilateral adrenal cortisol-producing adenomas, primary pigmented nodular adrenocortical disease (PPNAD), or pituitary corticotroph adenomas (Cushing's disease).</p><p>The majority of patients with BMAH have only subclinical cortisol production and present with bilateral adrenal incidentalomas [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/1\" class=\"abstract_t\">1</a>]. In these patients, no symptoms of Cushing's syndrome may be present, and the nodular adrenals are identified when abdominal imaging (ultrasound, computed tomography [CT] scan, or magnetic resonance imaging [MRI]) are performed for unrelated reasons.</p><p>In patients in whom cortisol secretion is sufficient to produce mild or overt Cushing's syndrome, the symptoms and signs are similar to other etiologies of primary adrenal Cushing's syndrome. (See <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Cushing's syndrome&quot;</a>.)</p><p>Primary BMAH is associated with adrenal glands weighing from 25 to 500 g (normal range 4 to 6 g per adrenal) that contain multiple nonpigmented nodules greater than 10 mm in diameter [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/46-48\" class=\"abstract_t\">46-48</a>]. The enlargement of the adrenal glands is not associated with pain. The nodules appear to be typical benign adrenal nodules, but the internodular cortex may be either hyperplastic (in most cases) or atrophic. BMAH may present with asynchronous nodular hyperplasia in one gland and later in the contralateral gland [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/1,36,58\" class=\"abstract_t\">1,36,58</a>].</p><p class=\"headingAnchor\" id=\"H890902628\"><span class=\"h1\">INITIAL EVALUATION</span></p><p class=\"headingAnchor\" id=\"H1078947906\"><span class=\"h2\">Biochemical testing</span></p><p class=\"headingAnchor\" id=\"H3233105941\"><span class=\"h3\">Bilateral incidentalomas and mild cortisol excess</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with BMAH present with bilateral incidentalomas and mild cortisol excess. Their initial evaluation is similar to that for a unilateral incidentaloma and includes tests to look for hormonal hypersecretion, most importantly, the degree of cortisol excess (Cushing's syndrome), but also catecholamine and aldosterone excess (eg, pheochromocytomas and aldosteronomas) (see <a href=\"topic.htm?path=the-adrenal-incidentaloma#H17\" class=\"medical medical_review\">&quot;The adrenal incidentaloma&quot;, section on 'Evaluation for hormonal secretion'</a> and <a href=\"topic.htm?path=the-adrenal-incidentaloma#H18\" class=\"medical medical_review\">&quot;The adrenal incidentaloma&quot;, section on 'Subclinical Cushing's syndrome'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>1 mg overnight <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> suppression test</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>24-hour urinary metanephrine or plasma free metanephrine levels</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">Aldosterone/renin</span> ratio (only if the patient has hypertension)</p><p/><p>In <strong>contrast</strong> with unilateral incidentalomas, the following additional testing is also indicated in patients with macronodules, including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early-morning cortisol and corticotropin (ACTH) levels to rule out primary adrenal insufficiency from bilateral <span class=\"nowrap\">infiltrative/infectious/metastatic</span> diseases.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A serum 17-hydroxyprogesterone level is measured to rule out nonclassic congenital adrenal hyperplasia (NCCAH) due to 21-hydroxylase deficiency, which may sometimes present as silent bilateral adrenal incidentalomas. (See <a href=\"topic.htm?path=diagnosis-and-treatment-of-nonclassic-late-onset-congenital-adrenal-hyperplasia-due-to-21-hydroxylase-deficiency#H151972333\" class=\"medical medical_review\">&quot;Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency&quot;, section on '17-hydroxyprogesterone'</a>.)</p><p/><p>As noted, the majority of patients with primary BMAH have no or mild clinical features of<strong> </strong>Cushing's syndrome. They have normal urinary free cortisol (UFC), detectable ACTH levels still responsive to corticotropin-releasing hormone (CRH), but with subnormal suppression of plasma cortisol following <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/2,3,9\" class=\"abstract_t\">2,3,9</a>]. In these patients, low- or high-dose dexamethasone will produce partial suppression of cortisol but not to &lt;1.8 <span class=\"nowrap\">mcg/dL</span> (50 <span class=\"nowrap\">nmol/L)</span> in the morning following nighttime 1 mg dexamethasone administration [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/2,7,9\" class=\"abstract_t\">2,7,9</a>].</p><p>After a nighttime dose of <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> (1 mg), a range of morning cortisol levels from 1.8 <span class=\"nowrap\">mcg/dL</span> (50 <span class=\"nowrap\">nmol/L)</span> to an intermediate level of 5 <span class=\"nowrap\">mcg/dL</span> (140 <span class=\"nowrap\">nmol/L)</span> to &gt;10 <span class=\"nowrap\">mcg/dL</span> (280 <span class=\"nowrap\">nmol/L)</span> can be seen.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with serum cortisol concentrations &gt;10 <span class=\"nowrap\">mcg/dL</span> typically have elevated UFC, suppressed ACTH, and progressive clinical signs of Cushing's syndrome.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Those between 1.8 and 10 <span class=\"nowrap\">mcg/dL</span> may have minimal clinical manifestations, but this is probably also affected by various factors, including duration of disease and glucocorticoid receptor sensitivity.</p><p/><p>One case of massive BMAH in a male patient was found to produce large amounts of adrenal androgens (dehydroepiandrosterone [DHEA], dehydroepiandrosterone sulfate [DHEAS]) without any cortisol excess (ACTH not suppressed) or clinical symptoms and was detected only as bilateral incidentaloma [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/77\" class=\"abstract_t\">77</a>].</p><p class=\"headingAnchor\" id=\"H4093639569\"><span class=\"h4\">Evaluate degree of cortisol excess</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>So, if the initial screening with 1 mg overnight <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> does not suppress cortisol to &lt;1.8 <span class=\"nowrap\">mcg/dL</span> (50 <span class=\"nowrap\">nmol/L),</span> we perform the following additional tests to evaluate the degree of cortisol oversecretion:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>24-hour UFC <strong>(twice)</strong>. (See <a href=\"topic.htm?path=establishing-the-diagnosis-of-cushings-syndrome#H7\" class=\"medical medical_review\">&quot;Establishing the diagnosis of Cushing's syndrome&quot;, section on '24-hour urinary cortisol excretion'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Salivary late-night cortisol <strong>(twice)</strong>. This is a screening test for Cushing's syndrome and is described in detail separately. (See <a href=\"topic.htm?path=establishing-the-diagnosis-of-cushings-syndrome#H9\" class=\"medical medical_review\">&quot;Establishing the diagnosis of Cushing's syndrome&quot;, section on 'Late-night salivary cortisol'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fasting ACTH (if not done previously). (See <a href=\"topic.htm?path=establishing-the-cause-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Establishing the cause of Cushing's syndrome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aldosterone-to-renin ratio is performed to detect mild aldosterone excess, even in the absence of hypertension, when UFC is elevated and ACTH suppressed. Co-secretion of aldosterone can be seen in BMAH. (See <a href=\"#H668811619\" class=\"local\">'Aberrant hormone receptors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Additional blood tests such as DHEAS levels, total <a href=\"topic.htm?path=testosterone-drug-information\" class=\"drug drug_general\">testosterone</a>, sex hormone-binding globulin (SHBG), and estradiol may be measured depending upon the clinical findings (eg, virilization in women, hypogonadism or gynecomastia in men, and patients with elevated UFC and suppressed ACTH).</p><p/><p class=\"headingAnchor\" id=\"H2583087092\"><span class=\"h3\">BMAH with overt Cushing's syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory findings are similar to those seen in ACTH-independent Cushing's syndrome with unilateral tumors and include the following (see <a href=\"topic.htm?path=establishing-the-cause-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Establishing the cause of Cushing's syndrome&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased serum and 24-hour UFC and low to undetectable plasma ACTH (&lt;5 <span class=\"nowrap\">pg/mL</span> [&lt;1.1 <span class=\"nowrap\">pmol/L])</span> in the basal state and after administration of CRH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/46-49\" class=\"abstract_t\">46-49</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased late-night salivary cortisol levels.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum DHEAS levels are usually suppressed as ACTH levels become suppressed.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cortisol production is not suppressed by low- or high-dose <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> tests.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An exception to this general pattern occurs in patients with gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome in whom cortisol hypersecretion occurs in response to meals and serum cortisol may be low in the fasting state [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/31,32\" class=\"abstract_t\">31,32</a>]. (See <a href=\"#H668811619\" class=\"local\">'Aberrant hormone receptors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Steroid hormone synthesis is relatively inefficient in BMAH, as a consequence of decreased steroidogenic enzymatic activity resulting frequently in elevated 17-hydroxyprogesterone levels basally or after stimulation with ACTH [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/4,9\" class=\"abstract_t\">4,9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Co-secretion of serum aldosterone, 18-hydroxycorticosterone, corticosterone, and <a href=\"topic.htm?path=estrone-united-states-not-available-drug-information\" class=\"drug drug_general\">estrone</a> may cause hypertension or feminization in the rare patients in whom they are increased [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/78\" class=\"abstract_t\">78</a>].</p><p/><p class=\"headingAnchor\" id=\"H968511918\"><span class=\"h2\">Imaging findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The results of adrenal computed tomography (CT) and magnetic resonance imaging (MRI) are variable, ranging from apparently unilateral nodules to massive bilateral enlargement [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/36,46-49,79\" class=\"abstract_t\">36,46-49,79</a>]. Multiple nodules may be seen that are greater than 10 mm in diameter but can be as large as 30 to 40 mm in diameter [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/1\" class=\"abstract_t\">1</a>] (55 mm in one study [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/79\" class=\"abstract_t\">79</a>]). However, in some cases, diffuse enlargement of both adrenals can be present without distinct nodules. In one series of 12 patients, 11 had enlarged multinodular glands; nine patients underwent pituitary CT or MRI, and all were normal [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/79\" class=\"abstract_t\">79</a>].</p><p>Adrenal scintigraphy with iodine-131 (131-I)-labeled cholesterol showed bilateral uptake in four of five patients in one report [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/79\" class=\"abstract_t\">79</a>]. Although not widely available, this imaging technique could help identify which gland to remove if one chooses unilateral adrenalectomy. A preliminary study indicated increased fluorodeoxyglucose-positron emission tomography (FDG-PET) signal in BMAH tissues despite absence of malignancy; the frequency of such increased FDG-signal uptake remains to be confirmed in larger cohorts [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/80,81\" class=\"abstract_t\">80,81</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of BMAH is made in patients with:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Overt Cushing's syndrome and suppressed corticotropin (ACTH) levels in whom bilaterally enlarged nodular adrenals are found at abdominal computed tomography (CT) scan (a minority of cases).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incidentally found bilateral adrenal hyperplasia with several macronodules in whom a subnormal suppression of cortisol is found (&gt;1.8 <span class=\"nowrap\">mcg/dL</span> or &gt;50 <span class=\"nowrap\">nmol/L)</span> following 1 mg overnight <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> suppression test (the majority of cases).</p><p/><p class=\"bulletIndent1\">However, in individuals with single nodules in each adrenal and subclinical cortisol secretion, the diagnosis could be bilateral adenomas or an early phase of BMAH.</p><p/><p class=\"headingAnchor\" id=\"H968511870\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary BMAH, a pituitary ACTH-independent form of Cushing's syndrome, must be distinguished from:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unilateral cortisol-producing adrenal adenomas</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary pigmented nodular adrenocortical disease (PPNAD)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Secondary ACTH-dependent macronodular adrenal hyperplasia</p><p/><p>Features that can help distinguish between these disorders include the following:</p><p>Primary BMAH versus secondary ACTH-dependent macronodular hyperplasias:</p><p>Measure plasma ACTH:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Plasma ACTH is suppressed by excess cortisol in primary BMAH (&lt;5 <span class=\"nowrap\">pg/mL</span> [&lt;1.1 <span class=\"nowrap\">pmol/L])</span>. In contrast, ACTH is inappropriately normal or slightly high in ACTH-dependent macronodular hyperplasia (&ge;15 <span class=\"nowrap\">pg/mL</span> [3.3 <span class=\"nowrap\">pmol/L])</span>. (See <a href=\"topic.htm?path=establishing-the-cause-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Establishing the cause of Cushing's syndrome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rare patients with ACTH-dependent hyperplasia have low but consistently detectable plasma ACTH concentrations (&le;10 <span class=\"nowrap\">pg/mL</span> [2.8 <span class=\"nowrap\">pmol/L]),</span> presumably due to its suppression by some of their adrenal nodules, which have acquired the capacity to secrete cortisol constitutively by unidentified mechanisms [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/82,83\" class=\"abstract_t\">82,83</a>]. (See <a href=\"topic.htm?path=establishing-the-cause-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Establishing the cause of Cushing's syndrome&quot;</a>.)</p><p/><p>Among the different primary adrenal sources of Cushing's syndrome, there are several features that are suggestive of BMAH:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with overt Cushing's syndrome due to BMAH present in the fifth and sixth decades [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/46-49\" class=\"abstract_t\">46-49</a>], a later age of onset compared with unilateral cortisol-producing adenomas or PPNAD.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Size of adrenal gland nodules usually clearly distinguish PPNAD (micronodular) from BMAH (macronodular).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>While the typical laboratory findings of BMAH with overt Cushing's syndrome include high fasting serum and urinary cortisol and suppressed plasma ACTH and dehydroepiandrosterone sulfate (DHEAS) concentrations [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/46-49\" class=\"abstract_t\">46-49</a>], an exception to this general pattern occurs in patients with BMAH and gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome, in whom cortisol hypersecretion occurs in response to meals [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/31,32\" class=\"abstract_t\">31,32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metastatic or infiltrative adrenal diseases &ndash; In BMAH, the increase in cortisol following administration of exogenous ACTH is greater than in normal adrenals and reflects the large adrenal cell mass [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/4,6\" class=\"abstract_t\">4,6</a>]. This biochemical finding can be useful in distinguishing BMAH from other causes of bilaterally enlarged adrenals such as metastatic or infiltrative diseases, where steroidogenic response to ACTH administration is decreased. In PPNAD, cortisol response is usually limited following exogenous ACTH stimulation.</p><p/><p class=\"headingAnchor\" id=\"H968512065\"><span class=\"h2\">Further evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Further evaluation is needed in patients diagnosed with BMAH and overt or mild Cushing's syndrome.</p><p class=\"headingAnchor\" id=\"H890902871\"><span class=\"h3\">Metabolic consequences of hypercortisolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once the diagnosis of BMAH is established, further evaluation is necessary to look for potential metabolic consequences of cortisol excess. Patients should undergo evaluation for<strong> </strong>glucose intolerance and type 2 diabetes (fasting glucose, glycated hemoglobin [A1C] levels, or oral glucose tolerance test [OGTT]), hypertension (including 24-hour monitoring if necessary), coronary heart disease, and bone health (bone mineral density and vertebral fracture assessment).</p><p class=\"headingAnchor\" id=\"H1559179074\"><span class=\"h3\">Screening for aberrant receptors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In our center and several other academic centers [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/1-7,9,11-17,19-21,23-27,31-37,40\" class=\"abstract_t\">1-7,9,11-17,19-21,23-27,31-37,40</a>], we suggest that patients with BMAH and clinical or mild Cushing's syndrome undergo screening for aberrant receptors as this may change the therapeutic strategy (<a href=\"image.htm?imageKey=ENDO%2F65003\" class=\"graphic graphic_table graphicRef65003 \">table 1</a>). Protocols have been developed to systematically evaluate for these aberrant receptors (<a href=\"image.htm?imageKey=ENDO%2F65003\" class=\"graphic graphic_table graphicRef65003 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/2-7,10\" class=\"abstract_t\">2-7,10</a>].</p><p>The strategy is to examine whether cortisol or other steroids change in response to physiological (upright posture, mixed meals) and pharmacologic (gonadotropin-releasing hormone [GnRH], <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a>, <a href=\"topic.htm?path=glucagon-drug-information\" class=\"drug drug_general\">glucagon</a>, <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">metoclopramide</a>) tests that modulate the levels of ligands for the potential aberrant receptors. Of note, thyrotropin-releasing hormone (TRH) testing has rarely yielded aberrant responses, and TRH is not widely available. We therefore do <strong>not</strong> consider TRH testing to be necessary when screening for aberrant receptors.</p><p>Another group has suggested restricting tests to those for which a therapy is possible, ie, mixed meal, posture test, and luteinizing hormone-releasing hormone (LHRH) test [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/84\" class=\"abstract_t\">84</a>]. As this disease is relatively rare, we recommend that patients be referred to expert centers that can offer detailed investigation capacity.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Screening family members</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>First-degree relatives (&gt;25 years of age) of patients with BMAH who do not carry armadillo repeat containing 5 gene (<em>ARMC5</em>) gene mutations should be screened for BMAH by first looking for evidence of hypercortisolism. This can be done with an overnight 1 mg <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> test; those who do not suppress their plasma cortisol on the following morning below 1.8 <span class=\"nowrap\">mcg/dL</span> (50 <span class=\"nowrap\">nmol/L)</span> should undergo adrenal CT scan to look for possible features of BMAH (adrenal nodules, bilateral enlargement). (See <a href=\"topic.htm?path=dexamethasone-suppression-tests#H5\" class=\"medical medical_review\">&quot;Dexamethasone suppression tests&quot;, section on 'Overnight screening test'</a> and <a href=\"#H968511918\" class=\"local\">'Imaging findings'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Family members who are found to have BMAH should undergo detailed biochemical and clinical investigation described above and targeted evaluation for the aberrant hormone receptors that were found in the initial case if it can lead to specific targeted medical therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with BMAH associated with other genetic causes such as multiple endocrine neoplasia syndrome type 1 (MEN1) or familial adenomatous polyposis should undergo the recommended <span class=\"nowrap\">evaluation/screening</span> for those disorders. (See <a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis#H14907078\" class=\"medical medical_review\">&quot;Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis&quot;, section on 'Screening for MEN1-associated tumors'</a> and <a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families\" class=\"medical medical_review\">&quot;Familial adenomatous polyposis: Screening and management of patients and families&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The search for germline <em>ARMC5</em> mutations (and possibly other genes as more are identified) now allows familial screening through a simple blood test and identify who should undergo further evaluations [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/44,56\" class=\"abstract_t\">44,56</a>]. (See <a href=\"#H668811731\" class=\"local\">'Genetic causes'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial patients identified with BMAH were evaluated because of severe Cushing's syndrome and underwent bilateral adrenalectomy. However, considering the wide range of clinical presentations from asymptomatic bilateral incidentaloma cases to overt Cushing's syndrome, we currently recommend the following approaches based on severity of cortisol excess:</p><p class=\"headingAnchor\" id=\"H753019922\"><span class=\"h2\">Patients with BMAH and no aberrant receptors</span></p><p class=\"headingAnchor\" id=\"H2152867790\"><span class=\"h3\">Overt Cushing's syndrome</span></p><p class=\"headingAnchor\" id=\"H694974059\"><span class=\"h4\">Bilateral adrenalectomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest bilateral surgical adrenalectomy for patients with BMAH and severe Cushing's syndrome (elevated urinary free cortisol [UFC] &gt;3 times above upper limit of normal) who have <strong>no</strong> evidence of aberrant receptors that would be amenable to specific medical therapy. Surgical bilateral adrenalectomy is uniformly effective in these patients.</p><p>We agree with the Endocrine Society guidelines and suggest thromboprophylaxis in any patient with Cushing's syndrome going to surgery because of their high risk of thromboembolism [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/85\" class=\"abstract_t\">85</a>] (see <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-cushings-syndrome#H2088799761\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Cushing's syndrome&quot;, section on 'Thromboembolic events'</a>). Post-adrenalectomy, these patients will require lifetime glucocorticoid and mineralocorticoid replacement but are <strong>not</strong> at risk for Nelson syndrome (corticotroph tumor progression), because the pituitary is intrinsically normal. Therefore, pituitary radiation to prevent Nelson syndrome is unnecessary. (See <a href=\"topic.htm?path=persistent-or-recurrent-cushings-disease-surgical-adrenalectomy#H362181912\" class=\"medical medical_review\">&quot;Persistent or recurrent Cushing's disease: Surgical adrenalectomy&quot;, section on 'Nelson syndrome'</a>.)</p><p>Adrenal enzyme inhibitors are sometimes given to patients with overt Cushing's syndrome to control cortisol secretion before surgery, particularly if surgery needs to be delayed for some underlying condition such as infection, recent cerebrovascular or coronary event, or pulmonary emboli [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/86\" class=\"abstract_t\">86</a>]. (See <a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome#H18\" class=\"medical medical_review\">&quot;Medical therapy of hypercortisolism (Cushing's syndrome)&quot;, section on 'Adrenal enzyme inhibitors'</a>.)</p><p>Surgical adrenalectomy, including surgical approach and postoperative hormone replacement, is discussed in greater detail separately. (See <a href=\"topic.htm?path=persistent-or-recurrent-cushings-disease-surgical-adrenalectomy\" class=\"medical medical_review\">&quot;Persistent or recurrent Cushing's disease: Surgical adrenalectomy&quot;</a> and <a href=\"topic.htm?path=adrenalectomy-techniques\" class=\"medical medical_review\">&quot;Adrenalectomy techniques&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2441790401\"><span class=\"h3\">Modest cortisol excess</span></p><p class=\"headingAnchor\" id=\"H632468868\"><span class=\"h4\">Unilateral adrenalectomy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with moderately increased cortisol production (less than threefold increase in UFC levels) but with clinical evidence of cortisol excess, we suggest unilateral adrenalectomy as it can restore UFC levels to normal [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/87-90\" class=\"abstract_t\">87-90</a>]. However, as the cell mass subsequently increases in the contralateral adrenal, medical therapy with steroidogenesis inhibitors or a second adrenalectomy may become necessary [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/87-89,91\" class=\"abstract_t\">87-89,91</a>]. In 15 patients with BMAH treated by unilateral adrenalectomy, resection of the larger gland led to remission of hypercortisolism after three months in all 15 patients and a low risk of recurrence (2 of 15 [13 percent]) after seven to nine years of follow-up [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/91\" class=\"abstract_t\">91</a>]. Six patients had transient hypothalamic-pituitary-adrenal (HPA) insufficiency after unilateral adrenalectomy. Thus, careful postoperative evaluation of the HPA axis should be performed, and glucocorticoid replacement should be provided if needed. Glucocorticoids are then tapered as the axis recuperates over the following months.</p><p>We do not suggest adrenal venous sampling to select which adrenal to remove, as standardization for data interpretation are lacking. In the largest study of 10 patients, an <span class=\"nowrap\">adrenal/peripheral</span> vein ratio of &ge;6.5 was considered consistent with a cortisol hypersecretion, and a cortisol lateralization ratio of &le;2.0 was in favor of bilateral source of cortisol [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/92\" class=\"abstract_t\">92</a>].</p><p class=\"headingAnchor\" id=\"H1721628700\"><span class=\"h3\">Minimal cortisol excess</span></p><p class=\"headingAnchor\" id=\"H1559180438\"><span class=\"h4\">Monitoring without surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with very mild cortisol excess (normal UFC, normal corticotropin [ACTH], cortisol suppression following 1 mg overnight <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> &lt;5 <span class=\"nowrap\">mcg/dL)</span> who are being monitored without adrenal surgery, clinical evaluation and biochemical assessment (1 mg overnight dexamethasone test, UFC, basal ACTH, fasting glucose) every 6 to 12 months and yearly computed tomography (CT) scan are sufficient as BMAH is a benign process that has not been shown to become malignant.</p><p>We suggest unilateral adrenalectomy if there is disease progression with increased UFC, complete suppression of ACTH, and important clinical effects of hypercortisolism such as osteoporosis, diabetes, hypertension, or neuropsychological manifestations (see <a href=\"#H632468868\" class=\"local\">'Unilateral adrenalectomy'</a> above). As studies in unilateral adrenal incidentaloma have reported progressive adverse cardiovascular outcomes in patients with plasma cortisol &gt;5.1 <span class=\"nowrap\">mcg/dL</span> (140 <span class=\"nowrap\">nmol/L)</span> after a 1 mg <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> test [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/93,94\" class=\"abstract_t\">93,94</a>], we are more commonly referring patients to unilateral adrenalectomy when signs of cortisol excess develop.</p><p class=\"headingAnchor\" id=\"H677931018\"><span class=\"h2\">Patients with BMAH and aberrant receptors</span></p><p class=\"headingAnchor\" id=\"H21362891\"><span class=\"h3\">Pharmacologic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some patients in whom aberrant hormone receptors have been identified, specific pharmacologic therapies blocking the aberrant receptors can be effective as alternatives to adrenalectomy. Despite normalization of cortisol secretion with specific aberrant receptor-targeted therapy, no tumor regression has been observed; this may be secondary to incomplete receptor blockade or to the possibility that proliferation is regulated by armadillo repeat containing 5 gene (<em>ARMC5)</em> mutations or other secondary genetic events [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/3,39,56,95\" class=\"abstract_t\">3,39,56,95</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest beta blocker therapy for BMAH patients with Cushing's syndrome and aberrant beta-adrenergic receptors. In catecholamine-dependent Cushing's syndrome and BMAH, beta-adrenergic receptor antagonists (<a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a>) are effective in the long-term control of hypercortisolism [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/8,17,20\" class=\"abstract_t\">8,17,20</a>]. Propranolol can be started at 60 <span class=\"nowrap\">mg/day,</span> increasing every two weeks up to 320 <span class=\"nowrap\">mg/day</span> in two to three divided doses in order to achieve mid-normal levels of UFC. We suggest monitoring patients weekly initially for the first month (UFC, blood pressure, pulse), monthly for three months and every three months if stable afterwards.</p><p/><p class=\"bulletIndent1\">In patients who experience side effects such as nightmares or who have compliance problems with split doses of <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a>, we have used <a href=\"topic.htm?path=nadolol-drug-information\" class=\"drug drug_general\">nadolol</a>, another nonselective antagonist that is administered as a single daily dose (40 to 320 mg).</p><p/><p class=\"bulletIndent1\">Symptomatic bradycardia without reaching normalized UFC may limit the use of beta-adrenergic receptor antagonists so that bilateral adrenalectomy is required. If beta-adrenergic receptor antagonists do not normalize UFC, we suggest adrenalectomy. (See <a href=\"#H694974059\" class=\"local\">'Bilateral adrenalectomy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest gonadotropin-releasing hormone (GnRH) agonist therapy for patients with luteinizing hormone (LH) or human chorionic gonadotropin (hCG) receptors. In <span class=\"nowrap\">LH/hCG-dependent</span> BMAH and Cushing's syndrome, suppression of endogenous LH levels with long-acting <a href=\"topic.htm?path=leuprolide-drug-information\" class=\"drug drug_general\">leuprolide</a> acetate controlled steroid secretion and avoided bilateral adrenalectomy [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/21,23\" class=\"abstract_t\">21,23</a>]. We typically use a monthly dose of depot leuprolide acetate (3.75 mg intramuscular).</p><p/><p class=\"bulletIndent1\">Levels of 24-hour UFC, morning plasma cortisol, and LH levels are monitored two and four weeks after the first injection. Treatment is continued if UFC normalizes or improves at least by 50 percent within the first three months based upon two UFC samples each month. If UFC levels are not normalized within three months, unilateral or bilateral adrenalectomy is recommended, depending on levels of cortisol excess as described previously.</p><p/><p class=\"bulletIndent1\">For patients who are well controlled on GnRH agonist therapy, we suggest follow-up every three to four months for the first year (with UFC, morning plasma cortisol, and serum LH). Of note, we have followed patients every six months thereafter; some have remained controlled for more than 10 years. In premenopausal women or males, we suggest adding gonadal steroids to the GnRH agonist to avoid the consequences of hypogonadism (estrogen-progestin therapy in women and <a href=\"topic.htm?path=testosterone-drug-information\" class=\"drug drug_general\">testosterone</a> in men). We also suggest monitoring bone mineral density. (See <a href=\"topic.htm?path=endometriosis-long-term-treatment-with-gonadotropin-releasing-hormone-agonists#H207353414\" class=\"medical medical_review\">&quot;Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists&quot;, section on 'GnRH with add-back therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome, we suggest surgical adrenalectomy rather than pharmacologic therapy (see <a href=\"#H668811619\" class=\"local\">'Aberrant hormone receptors'</a> above). Pharmacologic blockade of postprandial release of GIP with <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> or <a href=\"topic.htm?path=pasireotide-drug-information\" class=\"drug drug_general\">pasireotide</a> leads to clinical and biochemical improvement of Cushing's syndrome, but the beneficial effect does not persist in the long term, probably because of eventual desensitization of somatostatin receptors in GIP-secreting duodenal K cells [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/32,33,37\" class=\"abstract_t\">32,33,37</a>]. Thus, we suggest surgical adrenalectomy in these patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When specific receptor antagonists for ACTH, <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a>, serotonin, GIP, or other aberrant receptors become available, a broader range of pharmacologic therapies could become useful [<a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/44,45\" class=\"abstract_t\">44,45</a>]. Until these become available, surgical adrenalectomy is recommended.</p><p/><p class=\"headingAnchor\" id=\"H3974919429\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-cushings-syndrome\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Diagnosis and treatment of Cushing's syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary bilateral macronodular adrenal hyperplasia (BMAH or PBMAH) has been described by various terms, including corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH), primary macronodular adrenal hyperplasia (PMAH), massive macronodular adrenocortical disease (MMAD), autonomous macronodular adrenal hyperplasia (AMAH), ACTH-independent massive bilateral adrenal disease (AIMBAD), and &quot;giant&quot; or &quot;huge&quot; macronodular adrenal disease. (See <a href=\"#H668811581\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>BMAH is more frequently familial than previously believed (autosomal dominant transmission), and approximately 25 percent of apparent sporadic cases carry a germline mutation of armadillo repeat containing 5 gene (<em>ARMC5</em>). The disease appears heterogeneous as several other genetic abnormalities can be rarely associated. (See <a href=\"#H668811731\" class=\"local\">'Genetic causes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>BMAH results in hypercortisolism through a number of mechanisms that are described above (see <a href=\"#H668811581\" class=\"local\">'Pathogenesis'</a> above). In the majority of patients with BMAH, cortisol appears to be regulated by a number of aberrant G-protein-coupled receptors (GPCRs) and by locally produced ACTH. Aberrant receptors include <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a>, serotonin 5-hydroxytryptamine 4 (5-HT4), gastric inhibitory polypeptide (GIP), beta-adrenergic, luteinizing hormone <span class=\"nowrap\">(LH)/human</span> chorionic gonadotropin (hCG), and others. (See <a href=\"#H668811619\" class=\"local\">'Aberrant hormone receptors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical presentation and biochemical findings of Cushing's syndrome in BMAH are similar to those seen in other types of ACTH-independent Cushing's syndrome. However, patients with BMAH typically have a later age of onset (fifth and sixth decades), and patients with GIP-dependent Cushing's syndrome have a unique pattern of cortisol hypersecretion (&quot;food dependent&quot;). (See <a href=\"#H668811619\" class=\"local\">'Aberrant hormone receptors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of BMAH is made in patients with overt Cushing's syndrome and suppressed ACTH and dehydroepiandrosterone sulfate (DHEAS) levels with bilaterally enlarged nodular adrenals. The diagnosis is also made in patients with incidentally found bilateral diffusely enlarged adrenals or with multinodular adrenals and mild hypercortisolism in whom a subnormal suppression of cortisol is found (&gt;1.8 <span class=\"nowrap\">mcg/dL</span> or &gt;50 <span class=\"nowrap\">nmol/L)</span> following 1 mg overnight <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> suppression test. (See <a href=\"#H15\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with BMAH can be distinguished from those with chronic ACTH-dependent Cushing's syndrome (Cushing's disease or ectopic ACTH) with bilateral nodular adrenal hyperplasia who have elevated ACTH levels. (See <a href=\"#H968511870\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend that patients with BMAH and clinical or mild Cushing's syndrome undergo screening for aberrant receptors as this may change the therapeutic strategy. (See <a href=\"#H668811619\" class=\"local\">'Aberrant hormone receptors'</a> above and <a href=\"#H1559179074\" class=\"local\">'Screening for aberrant receptors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition, we recommend screening of first-degree relatives of index cases without known genetic mutation using 1 mg overnight <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> suppression test for the presence of familial BMAH. Genetic screening for <em>ARMC5</em> (or eventually other genes responsible for BMAH) has become available to screen first-degree relatives of index cases. (See <a href=\"#H18\" class=\"local\">'Screening family members'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with BMAH in whom aberrant hormone receptors are not present or for which no specific pharmacologic blockade is available or effective:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest bilateral adrenalectomy for severe Cushing's syndrome with urinary free cortisol (UFC) &gt;3 times the upper limit of normal (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H694974059\" class=\"local\">'Bilateral adrenalectomy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients with moderately increased cortisol production (less than threefold increase in UFC levels) and clinical evidence of cortisol excess, we suggest unilateral adrenalectomy as it can restore UFC levels to normal (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>) (see <a href=\"#H632468868\" class=\"local\">'Unilateral adrenalectomy'</a> above). Such patients can present transient secondary adrenal insufficiency and require glucocorticoid replacement postoperatively.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients with BMAH and normal levels of urinary cortisol, the decision between observation and surgery should be based on biochemical (suppressed ACTH, elevated late-night salivary cortisol, and cortisol &gt;5 <span class=\"nowrap\">mg/dL</span> following 1 mg <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> overnight test) and clinical evidence of cortisol excess (hypertension, diabetes, osteoporosis, or neuropsychological manifestations). (See <a href=\"#H1721628700\" class=\"local\">'Minimal cortisol excess'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with BMAH and overt Cushing's syndrome regulated by aberrant receptors (see <a href=\"#H677931018\" class=\"local\">'Patients with BMAH and aberrant receptors'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest treatment with beta-blockers for patients with BMAH and aberrant beta-adrenergic receptors (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H21362891\" class=\"local\">'Pharmacologic therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest treatment with gonadotropin-releasing hormone (GnRH) agonists (and sex steroid replacement) for patients with BMAH and <span class=\"nowrap\">LH/hCG</span> receptors (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H21362891\" class=\"local\">'Pharmacologic therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/1\" class=\"nounderline abstract_t\">Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23:245.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/2\" class=\"nounderline abstract_t\">Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/3\" class=\"nounderline abstract_t\">Lacroix A, Baldacchino V, Bourdeau I, et al. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab 2004; 15:375.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/4\" class=\"nounderline abstract_t\">Lib&eacute; R, Coste J, Guignat L, et al. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. Eur J Endocrinol 2010; 163:129.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/5\" class=\"nounderline abstract_t\">Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94:2930.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/6\" class=\"nounderline abstract_t\">Mircescu H, Jilwan J, N'Diaye N, et al. Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome? J Clin Endocrinol Metab 2000; 85:3531.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/7\" class=\"nounderline abstract_t\">Hofland J, Hofland LJ, van Koetsveld PM, et al. ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11&beta;-hydroxylase. Orphanet J Rare Dis 2013; 8:142.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/8\" class=\"nounderline abstract_t\">El Ghorayeb N, Bourdeau I, Lacroix A. Multiple aberrant hormone receptors in Cushing's syndrome. Eur J Endocrinol 2015; 173:M45.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/9\" class=\"nounderline abstract_t\">Bourdeau I, D'Amour P, Hamet P, et al. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:5534.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/10\" class=\"nounderline abstract_t\">Bertherat J, Contesse V, Louiset E, et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J Clin Endocrinol Metab 2005; 90:1302.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/11\" class=\"nounderline abstract_t\">Horiba N, Suda T, Aiba M, et al. Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1995; 80:2336.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/12\" class=\"nounderline abstract_t\">Lacroix A, Tremblay J, Touyz RM, et al. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. J Clin Endocrinol Metab 1997; 82:2414.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/13\" class=\"nounderline abstract_t\">Mune T, Murase H, Yamakita N, et al. Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002; 87:5706.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/14\" class=\"nounderline abstract_t\">Miyamura N, Taguchi T, Murata Y, et al. Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine 2002; 19:319.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/15\" class=\"nounderline abstract_t\">Lee S, Hwang R, Lee J, et al. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clin Endocrinol (Oxf) 2005; 63:625.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/16\" class=\"nounderline abstract_t\">Vezzosi D, Cartier D, R&eacute;gnier C, et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol 2007; 156:21.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/17\" class=\"nounderline abstract_t\">Lacroix A, Tremblay J, Rousseau G, et al. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med 1997; 337:1429.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/18\" class=\"nounderline abstract_t\">Bourdeau I, Oble S, Magne F, et al. ARMC5 mutations in a large French-Canadian family with cortisol-secreting &beta;-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia. Eur J Endocrinol 2016; 174:85.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/19\" class=\"nounderline abstract_t\">Miyamura N, Tsutsumi A, Senokuchi H, et al. A case of ACTH-independent macronodular adrenal hyperplasia: simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocr J 2003; 50:333.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/20\" class=\"nounderline abstract_t\">Mazzuco TL, Thomas M, Martinie M, et al. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing's syndrome. Arq Bras Endocrinol Metabol 2007; 51:1452.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/21\" class=\"nounderline abstract_t\">Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome. N Engl J Med 1999; 341:1577.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/22\" class=\"nounderline abstract_t\">Pl&ouml;ckinger U, Chrusciel M, Doroszko M, et al. Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome. J Endocr Soc 2017; 1:57.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/23\" class=\"nounderline abstract_t\">Goodarzi MO, Dawson DW, Li X, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab 2003; 88:73.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/24\" class=\"nounderline abstract_t\">Feelders RA, Lamberts SW, Hofland LJ, et al. Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. J Clin Endocrinol Metab 2003; 88:230.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/25\" class=\"nounderline abstract_t\">Cartier D, Lihrmann I, Parmentier F, et al. Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2003; 88:248.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/26\" class=\"nounderline abstract_t\">Mannelli M, Ferruzzi P, Luciani P, et al. Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88:4616.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/27\" class=\"nounderline abstract_t\">Louiset E, Contesse V, Groussin L, et al. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:4578.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/28\" class=\"nounderline abstract_t\">Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123:509.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/29\" class=\"nounderline abstract_t\">Burgess JR, Harle RA, Tucker P, et al. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 1996; 131:699.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/30\" class=\"nounderline abstract_t\">Swords FM, Baig A, Malchoff DM, et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol 2002; 16:2746.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/31\" class=\"nounderline abstract_t\">Lacroix A, Bolt&eacute; E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. N Engl J Med 1992; 327:974.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/32\" class=\"nounderline abstract_t\">Reznik Y, Allali-Zerah V, Chayvialle JA, et al. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992; 327:981.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/33\" class=\"nounderline abstract_t\">de Herder WW, Hofland LJ, Usdin TB, et al. Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab 1996; 81:3168.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/34\" class=\"nounderline abstract_t\">Groussin L, Perlemoine K, Contesse V, et al. The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab 2002; 87:1980.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/35\" class=\"nounderline abstract_t\">N'Diaye N, Tremblay J, Hamet P, et al. Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome. J Clin Endocrinol Metab 1998; 83:2781.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/36\" class=\"nounderline abstract_t\">N'Diaye N, Hamet P, Tremblay J, et al. Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome. J Clin Endocrinol Metab 1999; 84:2616.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/37\" class=\"nounderline abstract_t\">Preumont V, Mermejo LM, Damoiseaux P, et al. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome. Horm Metab Res 2011; 43:287.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/38\" class=\"nounderline abstract_t\">Lampron A, Bourdeau I, Oble S, et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009; 94:750.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/39\" class=\"nounderline abstract_t\">Lampron A, Bourdeau I, Hamet P, et al. Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:3611.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/40\" class=\"nounderline abstract_t\">Albiger NM, Occhi G, Mariniello B, et al. Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. Eur J Endocrinol 2007; 157:771.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/41\" class=\"nounderline abstract_t\">Nakamura Y, Son Y, Kohno Y, et al. Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II. Endocrine 2001; 15:57.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/42\" class=\"nounderline abstract_t\">Assie G, Louiset E, Sturm N, et al. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J Clin Endocrinol Metab 2010; 95:E253.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/43\" class=\"nounderline abstract_t\">Emms H, Tsirou I, Cranston T, et al. Do patients with incidentally discovered bilateral adrenal nodules represent an early form of ARMC5-mediated bilateral macronodular hyperplasia? Endocrine 2016; 53:801.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/44\" class=\"nounderline abstract_t\">Lacroix A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013; 369:2147.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/45\" class=\"nounderline abstract_t\">Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013; 369:2115.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/46\" class=\"nounderline abstract_t\">KIRSCHNER MA, POWELL RD Jr, LIPSETT MB. CUSHING'S SYNDROME: NODULAR CORTICAL HYPERPLASIA OF ADRENAL GLANDS WITH CLINICAL AND PATHOLOGICAL FEATURES SUGGESTING ADRENOCORTICAL TUMOR. J Clin Endocrinol Metab 1964; 24:947.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/47\" class=\"nounderline abstract_t\">Cheitlin RA, Westphal M, Cabrera CM, et al. Cushing's syndrome due to bilateral adrenal macronodular hyperplasia with undetectable ACTH: cell culture of adenoma cells on extracellular matrix. Horm Res 1988; 29:162.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/48\" class=\"nounderline abstract_t\">Malchoff CD, Rosa J, DeBold CR, et al. Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. J Clin Endocrinol Metab 1989; 68:855.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/49\" class=\"nounderline abstract_t\">Swain JM, Grant CS, Schlinkert RT, et al. Corticotropin-independent macronodular adrenal hyperplasia: a clinicopathologic correlation. Arch Surg 1998; 133:541.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/50\" class=\"nounderline abstract_t\">Findlay JC, Sheeler LR, Engeland WC, Aron DC. Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 1993; 76:189.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/51\" class=\"nounderline abstract_t\">Minami S, Sugihara H, Sato J, et al. ACTH independent Cushing's syndrome occurring in siblings. Clin Endocrinol (Oxf) 1996; 44:483.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/52\" class=\"nounderline abstract_t\">Nies C, Bartsch DK, Ehlenz K, et al. Familial ACTH-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Exp Clin Endocrinol Diabetes 2002; 110:277.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/53\" class=\"nounderline abstract_t\">Im&ouml;hl M, K&ouml;ditz R, Stachon A, et al. [Catecholamine-dependent hereditary Cushing's syndrome - follow-up after unilateral adrenalectomy]. Med Klin (Munich) 2002; 97:747.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/54\" class=\"nounderline abstract_t\">Koyano H, Someya T, Osawa Y. ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) in two brothers and a sister. Folia Endocrinol 1996; 72:762.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/55\" class=\"nounderline abstract_t\">Watson TD, Patel SJ, Nardi PM. Case 121: familial adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing syndrome. Radiology 2007; 244:923.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/56\" class=\"nounderline abstract_t\">Assi&eacute; G, Lib&eacute; R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 2013; 369:2105.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/57\" class=\"nounderline abstract_t\">Faucz FR, Zilbermint M, Lodish MB, et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J Clin Endocrinol Metab 2014; 99:E1113.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/58\" class=\"nounderline abstract_t\">Alencar GA, Lerario AM, Nishi MY, et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. J Clin Endocrinol Metab 2014; 99:E1501.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/59\" class=\"nounderline abstract_t\">Espiard S, Drougat L, Lib&eacute; R, et al. ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences. J Clin Endocrinol Metab 2015; 100:E926.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/60\" class=\"nounderline abstract_t\">Correa R, Zilbermint M, Berthon A, et al. The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia. Eur J Endocrinol 2015; 173:435.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/61\" class=\"nounderline abstract_t\">Gagliardi L, Schreiber AW, Hahn CN, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2014; 99:E1784.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/62\" class=\"nounderline abstract_t\">Elbelt U, Trovato A, Kloth M, et al. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J Clin Endocrinol Metab 2015; 100:E119.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/63\" class=\"nounderline abstract_t\">Swords FM, Aylwin S, Perry L, et al. The aberrant expression of the gastric inhibitory polypeptide (GIP) receptor in adrenal hyperplasia: does chronic adrenocorticotropin exposure stimulate up-regulation of GIP receptors in Cushing's disease? J Clin Endocrinol Metab 2005; 90:3009.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/64\" class=\"nounderline abstract_t\">Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996; 75:171.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/65\" class=\"nounderline abstract_t\">Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/66\" class=\"nounderline abstract_t\">Boston BA, Mandel S, LaFranchi S, Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab 1994; 79:890.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/67\" class=\"nounderline abstract_t\">Fragoso MC, Domenice S, Latronico AC, et al. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 2003; 88:2147.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/68\" class=\"nounderline abstract_t\">Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur J Endocrinol 2012; 166:269.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/69\" class=\"nounderline abstract_t\">Kartheuser A, Walon C, West S, et al. Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3' APC mutation. J Med Genet 1999; 36:65.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/70\" class=\"nounderline abstract_t\">Matyakhina L, Freedman RJ, Bourdeau I, et al. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. J Clin Endocrinol Metab 2005; 90:3773.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/71\" class=\"nounderline abstract_t\">Lib&eacute; R, Fratticci A, Coste J, et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008; 14:4016.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/72\" class=\"nounderline abstract_t\">Skogseid B, Larsson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992; 75:76.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/73\" class=\"nounderline abstract_t\">Oheda T, Noguchi Y, Morio H, et al. Study on steroidogenic activity of ACTH-independent macronodular adrenocortical hyperplasia which occurred in brothers in a cancer family. Folia Endocrinologica 1995; 71:416.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/74\" class=\"nounderline abstract_t\">De Venanzi A, Alencar GA, Bourdeau I, et al. Primary bilateral macronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2014; 21:177.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/75\" class=\"nounderline abstract_t\">Fragoso MC, Alencar GA, Lerario AM, et al. Genetics of primary macronodular adrenal hyperplasia. J Endocrinol 2015; 224:R31.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/76\" class=\"nounderline abstract_t\">Drougat L, Espiard S, Bertherat J. Genetics of primary bilateral macronodular adrenal hyperplasia: a model for early diagnosis of Cushing's syndrome? Eur J Endocrinol 2015; 173:M121.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/77\" class=\"nounderline abstract_t\">Ghayee HK, Rege J, Watumull LM, et al. Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome. J Clin Endocrinol Metab 2011; 96:E243.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/78\" class=\"nounderline abstract_t\">Wada S, Kitahama S, Togashi A, et al. Preclinical Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia with excessive secretion of 18-hydroxydeoxycorticosterone and corticosterone. Intern Med 2002; 41:304.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/79\" class=\"nounderline abstract_t\">Doppman JL, Chrousos GP, Papanicolaou DA, et al. Adrenocorticotropin-independent macronodular adrenal hyperplasia: an uncommon cause of primary adrenal hypercortisolism. Radiology 2000; 216:797.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/80\" class=\"nounderline abstract_t\">Alencar GA, Fragoso MC, Yamaga LY, et al. (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake. J Clin Endocrinol Metab 2011; 96:3300.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/81\" class=\"nounderline abstract_t\">Cavalcante IP, Zerbini MC, Alencar GA, et al. High 18F-FDG uptake in PMAH correlated with normal expression of Glut1, HK1, HK2, and HK3. Acta Radiol 2016; 57:370.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/82\" class=\"nounderline abstract_t\">Aron DC, Findling JW, Fitzgerald PA, et al. Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med 1981; 71:302.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/83\" class=\"nounderline abstract_t\">Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J Clin Endocrinol Metab 1984; 58:25.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/84\" class=\"nounderline abstract_t\">Vassiliadi DA, Ntali G, Stratigou T, et al. Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine 2011; 40:437.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/85\" class=\"nounderline abstract_t\">Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:2807.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/86\" class=\"nounderline abstract_t\">Malchoff CD, MacGillvray D, Malchoff DM. Adrenocortical hormone-independent adrenal hyperplasia. Endocrinologist 1996; 6:79.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/87\" class=\"nounderline abstract_t\">Boronat M, Lucas T, Barcel&oacute; B, et al. Cushing's syndrome due to autonomous macronodular adrenal hyperplasia: long-term follow-up after unilateral adrenalectomy. Postgrad Med J 1996; 72:614.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/88\" class=\"nounderline abstract_t\">Lamas C, Alfaro JJ, Lucas T, et al. Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia?: Long-term follow-up of four cases. Eur J Endocrinol 2002; 146:237.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/89\" class=\"nounderline abstract_t\">Iacobone M, Albiger N, Scaroni C, et al. The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH). World J Surg 2008; 32:882.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/90\" class=\"nounderline abstract_t\">Xu Y, Rui W, Qi Y, et al. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World J Surg 2013; 37:1626.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/91\" class=\"nounderline abstract_t\">Debillon E, Velayoudom-Cephise FL, Salenave S, et al. Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab 2015; 100:4417.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/92\" class=\"nounderline abstract_t\">Young WF Jr, du Plessis H, Thompson GB, et al. The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses. World J Surg 2008; 32:856.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/93\" class=\"nounderline abstract_t\">Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2:396.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/94\" class=\"nounderline abstract_t\">Debono M, Bradburn M, Bull M, et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99:4462.</a></li><li><a href=\"https://www.uptodate.com/contents/cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia/abstract/95\" class=\"nounderline abstract_t\">Almeida MQ, Harran M, Bimpaki EI, et al. Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. J Clin Endocrinol Metab 2011; 96:E728.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 148 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1559178543\" id=\"outline-link-H1559178543\">OVERVIEW</a></li><li><a href=\"#H668811581\" id=\"outline-link-H668811581\">PATHOGENESIS</a><ul><li><a href=\"#H668811619\" id=\"outline-link-H668811619\">Aberrant hormone receptors</a></li><li><a href=\"#H668811725\" id=\"outline-link-H668811725\">Paracrine secretion of ACTH</a></li><li><a href=\"#H668811731\" id=\"outline-link-H668811731\">Genetic causes</a></li></ul></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL FEATURES</a></li><li><a href=\"#H890902628\" id=\"outline-link-H890902628\">INITIAL EVALUATION</a><ul><li><a href=\"#H1078947906\" id=\"outline-link-H1078947906\">Biochemical testing</a><ul><li><a href=\"#H3233105941\" id=\"outline-link-H3233105941\">- Bilateral incidentalomas and mild cortisol excess</a><ul><li><a href=\"#H4093639569\" id=\"outline-link-H4093639569\">Evaluate degree of cortisol excess</a></li></ul></li><li><a href=\"#H2583087092\" id=\"outline-link-H2583087092\">- BMAH with overt Cushing's syndrome</a></li></ul></li><li><a href=\"#H968511918\" id=\"outline-link-H968511918\">Imaging findings</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">DIAGNOSIS</a><ul><li><a href=\"#H968511870\" id=\"outline-link-H968511870\">Differential diagnosis</a></li><li><a href=\"#H968512065\" id=\"outline-link-H968512065\">Further evaluation</a><ul><li><a href=\"#H890902871\" id=\"outline-link-H890902871\">- Metabolic consequences of hypercortisolism</a></li><li><a href=\"#H1559179074\" id=\"outline-link-H1559179074\">- Screening for aberrant receptors</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Screening family members</a></li></ul></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">TREATMENT</a><ul><li><a href=\"#H753019922\" id=\"outline-link-H753019922\">Patients with BMAH and no aberrant receptors</a><ul><li><a href=\"#H2152867790\" id=\"outline-link-H2152867790\">- Overt Cushing's syndrome</a><ul><li><a href=\"#H694974059\" id=\"outline-link-H694974059\">Bilateral adrenalectomy</a></li></ul></li><li><a href=\"#H2441790401\" id=\"outline-link-H2441790401\">- Modest cortisol excess</a><ul><li><a href=\"#H632468868\" id=\"outline-link-H632468868\">Unilateral adrenalectomy</a></li></ul></li><li><a href=\"#H1721628700\" id=\"outline-link-H1721628700\">- Minimal cortisol excess</a><ul><li><a href=\"#H1559180438\" id=\"outline-link-H1559180438\">Monitoring without surgery</a></li></ul></li></ul></li><li><a href=\"#H677931018\" id=\"outline-link-H677931018\">Patients with BMAH and aberrant receptors</a><ul><li><a href=\"#H21362891\" id=\"outline-link-H21362891\">- Pharmacologic therapy</a></li></ul></li></ul></li><li><a href=\"#H3974919429\" id=\"outline-link-H3974919429\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/148|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/65003\" class=\"graphic graphic_table\">- Aberrant receptor screen</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adrenalectomy-techniques\" class=\"medical medical_review\">Adrenalectomy techniques</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-pathophysiology-of-cushings-syndrome\" class=\"medical medical_review\">Causes and pathophysiology of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of familial adenomatous polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cushings-syndrome-due-to-primary-pigmented-nodular-adrenocortical-disease\" class=\"medical medical_review\">Cushing's syndrome due to primary pigmented nodular adrenocortical disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty\" class=\"medical medical_review\">Definition, etiology, and evaluation of precocious puberty</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dexamethasone-suppression-tests\" class=\"medical medical_review\">Dexamethasone suppression tests</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-treatment-of-nonclassic-late-onset-congenital-adrenal-hyperplasia-due-to-21-hydroxylase-deficiency\" class=\"medical medical_review\">Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endometriosis-long-term-treatment-with-gonadotropin-releasing-hormone-agonists\" class=\"medical medical_review\">Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-cushings-syndrome\" class=\"medical medical_review\">Epidemiology and clinical manifestations of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=establishing-the-cause-of-cushings-syndrome\" class=\"medical medical_review\">Establishing the cause of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=establishing-the-diagnosis-of-cushings-syndrome\" class=\"medical medical_review\">Establishing the diagnosis of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families\" class=\"medical medical_review\">Familial adenomatous polyposis: Screening and management of patients and families</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hereditary-kidney-cancer-syndromes\" class=\"medical medical_review\">Hereditary kidney cancer syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-therapy-of-hypercortisolism-cushings-syndrome\" class=\"medical medical_review\">Medical therapy of hypercortisolism (Cushing's syndrome)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=persistent-or-recurrent-cushings-disease-surgical-adrenalectomy\" class=\"medical medical_review\">Persistent or recurrent Cushing's disease: Surgical adrenalectomy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-cushings-syndrome\" class=\"medical medical_society_guidelines\">Society guideline links: Diagnosis and treatment of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-adrenal-incidentaloma\" class=\"medical medical_review\">The adrenal incidentaloma</a></li></ul></div></div>","javascript":null}